trastuzumab
FDA Approves Ontruzant, Biosimilar to Herceptin
Ontruzant was approved for all eligible indications as the reference product: as an adjuvant therapy for ...
JANUARY 22, 2019
FDA Approves Herzuma for Breast Cancer
The FDA approved Herzuma, a HER2/neu receptor antagonist biosimilar to Herceptin for breast cancer treatment.
DECEMBER 17, 2018
FDA Approves Biosimilar Ogivri for Breast, Stomach Cancers
Ogivri is the first biosimilar approved in the United States for the treatment of breast cancer or stomach ...
DECEMBER 1, 2017
Load more